



**Baker IDI Research Online**

<http://library.bakeridi.edu.au>

This is the postprint version of the work. It is the manuscript that was accepted by the journal following peer review. It does not include the publisher's layout and pagination.

**"Ling LH, McLellan AJ, Taylor AJ, Iles LM, Ellims AH, Kumar S, Teh A, Lee G, Wong MC, Azzopardi S, Sellenger MA, Morton JB, Kalman JM, Kistler PM. Magnetic resonance post-contrast T1 mapping in the human atrium: validation and impact on clinical outcome following catheter ablation for atrial fibrillation. Heart Rhythm 2014; 11(9): 1551-9"**

<http://hdl.handle.net/11187/1990>

**Title**

Magnetic Resonance Contrast-enhanced T<sub>1</sub> Mapping in the Human Atrium: Validation and Impact on Clinical Outcome Following Catheter Ablation for Atrial Fibrillation

**Authors**

Liang-han Ling MBBS,<sup>1,2</sup> Alex McLellan\* MBBS,<sup>1,2</sup> Andrew J Taylor MBBS PhD,<sup>1</sup> Leah M Iles MBBS,<sup>1</sup> Andris H Ellims MBBS,<sup>1</sup> Saurabh Kumar MBBS,<sup>2</sup> Andrew Teh MBBS PhD,<sup>1,2</sup> Geoffrey Lee MBBS,<sup>1,2</sup> Michael Wong MBBS,<sup>1,2</sup> Michael A Sellenger BAppSci MHealthSc,<sup>1</sup> Jonathan M Kalman MBBS PhD,<sup>2</sup> Peter M Kistler MBBS PhD<sup>1</sup>

\*Dr McLellan is co-first author.

**Affiliations**

<sup>1</sup>Department of Cardiovascular Medicine, Alfred Hospital and Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia; <sup>2</sup>Cardiology Department, Royal Melbourne Hospital, Faculty of Medicine, Dentistry, and Health Sciences, University of Melbourne, Victoria, Australia

**Corresponding Author**

A/Prof Peter Kistler

Baker IDI Heart and Diabetes Institute

75 Commercial Road, Melbourne, Victoria, Australia 3004

Tel: 03 85321111, Fax: 03 85321111, Email: peter.kistler@bakeridi.edu.au

**Word Count**

4730 words

**Brief Title**

Atrial T<sub>1</sub> Mapping in the Human Atrium

**Financial Support**

Dr Ling is supported by an Australian National Heart Foundation (NHF) Postgraduate Scholarship. Drs. Drs McLellan, Ellims and Kumar are each supported by a co-funded NHMRC/NHF Postgraduate Scholarships. Drs Iles and Lee are each supported by an Australian National Health and Medical Research Council (NHMRC) Postgraduate Research Scholarship. Dr Taylor is supported by an NHMRC program grant, and an NHF project grant. . A/Professor Kistler is supported by a practitioner fellowship from the NHMRC. This research is supported in part by the Victorian Government's Operational Infrastructure Funding. All authors have reported no financial relationships to disclose.

## **Abstract**

**Objective:** To validate and assess the impact of cardiac magnetic resonance imaging (CMR) atrial T<sub>1</sub> mapping on the clinical outcome following catheter ablation for atrial fibrillation (AF).

**Background:** Atrial fibrosis is a pathologic correlate of atrial fibrillation (AF) and is accompanied by electrophysiologic remodeling.

**Methods:** CMR was performed in 3 groups using a clinical 1.5-T scanner: controls, paroxysmal AF (PAF) patients and persistent AF (PeAF) patients. A T<sub>1</sub> mapping sequence was used to calculate the post-contrast T<sub>1</sub> relaxation time (T<sub>1</sub> time) at the interatrial septum as an index of diffuse fibrosis. A subset of 23 AF subjects underwent left atrial endocardial bipolar voltage mapping for electrophysiologic correlation. Following AF ablation, patients underwent clinical assessment and 7-day holter monitoring at 6-monthly intervals for freedom from recurrent arrhythmia.

**Results:** 20 controls, 71 PAF patients, and 41 PeAF patients underwent CMR. Atrial T<sub>1</sub> time progressively shortened across groups (controls: 307±39 ms, PAF patients 260±41 ms, PeAF patients: 240±31 ms, p<0.001). Atrial T<sub>1</sub> time correlated with mean septal voltage (R<sup>2</sup>=0.47, p<0.001) and global LA voltage (R<sup>2</sup>=0.48, p<0.001). Advancing age, a diagnosis of AF, and AF duration independently predicted shortened atrial T<sub>1</sub> time (F=9.69, p<0.001). The single procedure success rate was 74% at 12±5 months post-ablation. Atrial T<sub>1</sub> time and AF category independently predicted arrhythmia recurrence (adjusted R<sup>2</sup>=0.29, p<0.01).

**Conclusion:** Atrial T<sub>1</sub> time as measured using CMR provides an index of atrial fibrosis that correlates with tissue voltage, AF type and clinical outcomes following catheter ablation.

## List of Abbreviations

AF	atrial fibrillation
ANOVA	analysis of variance
CMR	cardiac magnetic resonance
CS	coronary sinus
DE	delayed-enhancement
EF	ejection fraction
GFR	glomerular filtration rate
LA	left atrium/atrial
LV	left ventricle/ventricular
ROI	region of interest

## **Keywords**

Atrial fibrosis

Atrial fibrillation

Atrial remodelling

Cardiac magnetic resonance

T<sub>1</sub> mapping

## **Introduction**

The seminal observation that “AF begets AF” introduced the concept of electrical and structural remodeling fundamental to an understanding of the pathophysiology of atrial fibrillation (AF).(1) Following reversion to sinus rhythm, atrial electrical remodeling recovers within days, yet vulnerability to recurrent AF remains. Atrial structural remodeling, the hallmark of which is interstitial fibrosis is the second factor largely responsible for late AF recurrence. Atrial fibrosis is associated both with AF and with risk factors for AF including ageing and hypertension.(2) Given its negative impact on AF ablation outcomes,(3) non-invasive methods to quantify atrial fibrosis are of considerable potential clinical value.

Marrouche and co-workers have elegantly quantified the spatial extent of abnormal left atrial (LA) tissue using delayed-enhancement cardiac magnetic resonance imaging (DE-CMR). Findings were validated semi-quantitatively against extent of low-voltage tissue on electroanatomic maps derived at the time of AF ablation. (3) DE-CMR accurately defines regions of myocardial replacement fibrosis because these areas have a slower washout rate of gadolinium contrast than non-fibrotic myocardium, resulting in increased signal intensity on T<sub>1</sub>-weighted imaging. DE-CMR is a qualitative technique and requires presence of normal myocardium as a frame of reference to generate image contrast. In contrast, myocardial T<sub>1</sub> mapping allows direct signal quantification and has been validated against collagen content in animal models,(4,5) and in human cardiomyopathy.(6) Iles and co-workers showed that cardiomyopathy was associated with altered ventricular post-contrast T<sub>1</sub> relaxation time (T<sub>1</sub> time) in regions both with and without DE, establishing the technique’s greater sensitivity for detecting myocardial fibrosis over conventional DE-CMR.

To date DE-CMR of the atria has not become widely adopted. This study aims to validate atrial T<sub>1</sub> mapping as an index of atrial fibrosis and to explore its clinical utility in the setting of AF and impact on AF ablation outcomes.

## **Methods**

### *Study Population*

The study, approved by the Alfred Human Research Ethics Committee, was performed at the Alfred Hospital, Melbourne, Australia between October 2009 and November 2011. Recruits included healthy volunteers and symptomatic AF patients resistant to or intolerant of  $\geq 1$  antiarrhythmic agent and scheduled for AF ablation. AF patients were categorized as “paroxysmal” (PAF) where episodes were self-terminating within 7 days, or “persistent” (PeAF) where episodes lasted  $>7$  days or required direct current reversion (DCR). Healthy volunteers on no medications and without cardiac disease, hypertension, diabetes, smoking, or acute illness were recruited as controls. Subjects with renal dysfunction, claustrophobia, or metallic prosthetic implants were excluded. Informed consent was obtained from all recruits.

### *CMR Protocol*

Sequences were acquired using a clinical 1.5-T scanner (Signa HD 1.5-T, GE Healthcare, Wisconsin, USA) during breath-holds 10 to 15 s. LV indices were determined using the biplane area-length method applied to 2- and 4-chamber long-axis views. The LA boundary was traced manually (4-chamber long-axis view) to yield the cross-sectional area. Gadolinium-diethylene triamine penta-acetic acid (0.2 mmol/kg bodyweight, maximum 20 mmol, Magnevist, Schering, Germany) was administered as a bolus. Left atrigraphy was performed in all AF patients.

A  $T_1$  mapping sequence described previously(6) was used to acquire images in the 4-chamber long-axis. This involved an electrocardiogram-triggered, inversion-recovery prepared, 2-dimensional fast gradient echo sequence employing variable temporal sampling of k-space (Global Applied Science Laboratory, GE Healthcare).(7) Ten images were acquired sequentially at increasing inversion times (75 to 750 ms) 15 min following the contrast bolus (repetition/echo time: 3.7 ms/1.2 ms, flip angle: 20°, acquisition matrix: 256 × 128, field of view: 36 × 27 cm, slice thickness: 8 mm, trigger delay: 300 ms, and views per segment: 24).

### *Evaluation of Atrial Fibrosis with $T_1$ Mapping*

The  $T_1$  mapping sequences were analyzed using a dedicated research software package (VizPack Version 7.2.0, Global Applied Science Laboratory, GE Healthcare) that enabled analysis of regions of interest (ROIs) to determine pixel-by-pixel and mean  $T_1$  time by fitting data acquired at various preparation times to the exponential curve  $M_z(t=TI) = M_0(A - Be^{-t/T_1})$  relating the sample magnetization  $M_z$  observed at time  $t=TI$  to the equilibrium magnetization  $M_0$  and sample  $T_1$ , where  $TI$  denotes inversion time for an inversion recovery experiment. For each image, an ROI was manually sampled at the interatrial septum to calculate mean  $T_1$  time for each subject (Figure 1). Other regions of the atria were not sampled because they fell beyond the limits of resolution in the majority of scans. For 10 subjects in each of the 3 study groups, one blinded reviewer performed  $T_1$  mapping on 2 independent occasions to evaluate intra-observer variability. Further, two blinded reviewers (1 electrophysiologist and 1 cardiac CMR specialist) performed  $T_1$  mapping independently on the 30 subjects to evaluate inter-observer variability.

#### *LA Voltage Mapping*

Anti-arrhythmic medications were withheld >5 half-lives prior to the procedure except for amiodarone, which was ceased 1 month prior to the procedure. Under general anesthesia, trans-esophageal echocardiography was performed to exclude LA thrombus. Intra-cardiac catheters were positioned according as previously defined(8) (i) a 10-pole coronary sinus (CS) catheter; (ii) a 6-pole His catheter; (iii) a 20-pole variable loop circular mapping catheter (Reflexion Spiral XX, St Jude Medical, Minneapolis, MN, USA), and (iv) a 4-mm externally irrigated-tip ablation catheter (Contact Therapy Cool Path Duo, St Jude Medical). Double trans-septal access was obtained using a BRK1 needle and SL1 sheath (St Jude Medical). Intravenous heparin was administered with a target activated clotting time of 350 s. Bipolar intra-cardiac electrograms and 12-lead surface ECG were recorded simultaneously on a digital amplifier system (EP Med Systems, West Berlin, NJ, USA).

LA voltage maps were created as shown in Figure 2 in a subset of AF patients who were in sinus rhythm at the time of CMR (performed 1 day prior to ablation) and on the day of the ablation. A fill threshold of 10 mm was used to ensure even distribution of collected points. Data were acquired using the multipolar circular mapping catheter, except in areas of inadequate endocardial contact where the ablation catheter was used instead. Endocardial contact was confirmed using electrogram characteristics, fluoroscopic visualization of catheter stability in relation to cardiac motion, and distance-to-surface measurements.

Local bipolar voltage was defined as the amplitude between the absolute peak positive and peak negative deflections. Acquired points were annotated automatically then validated manually. Mean LA voltage was derived from the pool of validated points, and mean left septal voltage from points falling in the region of the interatrial septum.

### *Catheter Ablation*

Catheter ablation involved antral circumferential PV isolation as described previously(9). Power was limited to 30 watts (and 25W on the posterior wall) and temperature to 50°C. For persistent AF patients, if AF continued following PV isolation, a roof line joining the superior aspects of each wide encirclement ablation ring was deployed followed by electrical cardioversion. Roof line block was confirmed as previously described.(10) If AF organized to an atrial tachycardia (AT), activation mapping and targeted ablation was performed. Cavotricuspid isthmus ablation (40 Watts, 45°C) was performed for patients requiring cardioversion or having documented atrial flutter. Bidirectional conduction block was confirmed by differential pacing techniques and demonstration of widely-spaced double potentials along the CTI. A 30-minute waiting period following PV isolation was strictly employed. Adenosine 18 mg was administered intravenously with the spiral catheter positioned sequentially in the superior PVs to assess for transient PV reconnection. PVs were re-isolated if reconnection occurred. Patients remained in hospital for 48 hours post-procedure. Enoxaparin was administered 6 to 12 h post sheath removal (unless the procedure was performed on warfarin) and continued until a target INR >2 was achieved.

### *Follow up*

Patients were followed up clinically at 1, 3, 6 and 12 months, and on a 6-monthly basis thereafter, with 7-day holter monitoring performed at 6 monthly intervals. Additional assessments occurred where clinically indicated. Procedural success was defined as freedom from recurrent atrial arrhythmias lasting longer than 30 s after an initial 3-month blanking period while off antiarrhythmics, in keeping with consensus guidelines(11).

### *Statistics*

Data are expressed as mean±standard deviation (SD) unless otherwise indicated. Two-group comparisons were made using Student's t test and Fisher's exact test for continuous and categorical variables respectively. Three-group comparisons were made using 1-way analysis of variance (ANOVA) with Bonferroni correction for parametric variables and Kruskal-Wallis test with Dunn's post-test for nonparametric variables. Bland-Altman assessment compared intra- and inter-observer agreement between derived T<sub>1</sub> times. Simple and multiple linear regressions were used to assess relationships between continuous variables. Freedom from arrhythmia recurrence was assessed by binary logistic regression using univariate and multivariate models. Kaplan-Meier analysis was used to assess the impact of atrial T<sub>1</sub> time on procedural success. A two-tailed p value of <0.05 was considered significant. Analyses were conducted using SPSS software (version 17, SPSS, Chicago, Illinois).

## **Results**

### *Subject characteristics and CMR Findings*

Subject characteristics are shown in Table 1. Overall, 111 of 132 scans (84%) were performed in sinus rhythm and the remainder in AF including 11 (15%) paroxysmal AF (PAF) patients and 10 (24%) persistent AF (PeAF) patients (p=ns).

### *Intra- and Inter- Observer Correlation and Agreement*

R<sup>2</sup> values for the 10 T<sub>1</sub> data points fit to respective recovery curves were greater than 0.95 for all sequences analyzed. Intra- and inter observer T<sub>1</sub> times exhibited close correlation (Figure 3).

### *Relationship of Myocardial T<sub>1</sub> Time to LA Voltage*

Sixteen paroxysmal AF patients and 7 persistent AF patients underwent voltage mapping, with 31±12 left septal points and 336±96 LA points analyzed per subject. Atrial T<sub>1</sub> times (mean 242±32 ms) correlated positively with mean septal and mean LA voltage (Figures 4A and B).

### *Post-contrast Myocardial T<sub>1</sub> Times in Controls and AF subjects*

Atrial T<sub>1</sub> time was longest in controls and shortest in persistent AF subjects (Figure 4C). Among controls, there was no relationship between T<sub>1</sub> time and age, gender, or factors that could potentially influence gadolinium washout such as renal function, heart rate, and hematocrit (Table 2). Predictors of atrial T<sub>1</sub> time were evaluated among the entire cohort (Table 3). Again, there was no relationship between T<sub>1</sub> time and renal function, heart rate, or hematocrit. Age, a diagnosis of AF, and AF duration were independent predictors of atrial T<sub>1</sub> time (F=9.69, p<0.001).

#### *Procedural Characteristics and Outcomes*

Persistent AF patients had longer procedure times and higher radiation doses, and more frequently required intraprocedural DCR (Table 4). PV isolation was achieved in all patients. Acute PV reconnection occurred more frequently in paroxysmal versus persistent AF patients (40% vs 18%, p<0.05). All acutely reconnected PVs were successfully re-isolated. Single procedural success was achieved in 74% at 12±6 months. Arrhythmia recurrence occurred more frequently in persistent versus paroxysmal AF patients (39% vs 18%, p<0.05). Five paroxysmal and 7 persistent AF patients underwent a second catheter ablation procedure (7% vs 17%, p=ns).

#### *Impact of Atrial T<sub>1</sub> Time on Freedom from AF*

Atrial T<sub>1</sub> time was significantly shorter in patients with arrhythmia recurrence compared to those without (Table 5, 216±32 vs 245±42 ms, p<0.01). AF category and atrial T<sub>1</sub> time were significant independent predictors of arrhythmia recurrence (Table 6, adjusted R<sup>2</sup>=0.29, p<0.01). Freedom from AF occurred in 96% of patients with an atrial T<sub>1</sub> relaxation time >260ms and 68% in patients with atrial T<sub>1</sub> time <260ms (Figure 5, p<0.01).

## **Discussion**

This study describes contrast-enhanced T<sub>1</sub> mapping of the human atrial myocardium as a measure of tissue fibrosis and demonstrates that atrial T<sub>1</sub> times

- (i) can be measured reliably and reproducibly with minimal intra- and inter-observer variability;
- (ii) correlate with atrial tissue voltage at the interatrial septum and global LA;
- (iii) shorten with age and AF burden; and

- (iv) predict outcomes following AF ablation. An atrial T<sub>1</sub> relaxation time >260ms was associated with a 96% single procedure success rate following AF ablation.

#### *Non-invasive Assessment of Atrial Fibrosis*

Atrial fibrosis is the hallmark of structural remodeling and accompanies a variety of conditions associated with AF such as heart failure (12) and hypertension.(13) The landmark observation that “AF begets AF” is in part secondary to the profibrotic effects of AF itself.(14) The electrophysiologic sequelae of atrial fibrosis are characterized by slowed and heterogeneous conduction, which in turn promote multiple wavelets and localized reentry and establish a substrate favoring perpetuation of AF.(15)

There is presently no method for quantifying atrial fibrosis that is both widely available and widely accepted. Peripheral biomarkers of collagen turnover such as C-terminal propeptide and telopeptide of collagen type-I while elevated in AF subjects are not tissue specific and may reflect ventricular extracellular matrix remodeling associated with hypertension, heart failure, or AF itself. (16)

Echocardiographic studies of the LA have found integrated backscatter to correlate with LA appendage collagen content.(17) However, this technique assesses only the LA posterior wall, and is dependent on image acquisition parameters including ultrasound frequency, focus, and depth.

Marrouche and co-workers have elegantly described the use of DE-CMR to quantify spatial extent of LA remodeling in AF subjects, and correlated findings to abnormal electrophysiologic substrate and arrhythmia recurrence following AF ablation.(3) Extent of LA remodeling determined using DE-CMR has further been shown to reflect atrial mechanical function, predict atrial reverse remodeling following AF ablation, and predict stroke risk independently of CHADS<sub>2</sub> score.(18,19) Although atrial DE-MRI is compelling, results originate from a single clinical centre and are yet to be reproduced. While the application of DE-CMR to the LA represents a major advance in cardiac imaging and alludes to a wide range of exciting clinical and research applications, two important limitations should be noted. First, quantitation of the spatial extent of fibrosis is sensitive to the threshold intensity defining normal tissue, which is defined subjectively. Second, DE-CMR does not accurately quantify intensity of fibrosis, and may underestimate extent of fibrosis particularly where the atrium is diffusely diseased.

In the present study, T<sub>1</sub> time was quantified at the interatrial septum as the atrial myocardium elsewhere was too thin to be reliably assessed. Intra- and inter-observer reproducibility was high, and significant correlations with local and global tissue voltage indices were demonstrated. The pathophysiologic mechanisms responsible for atrial fibrosis may be triggered by AF itself or chronic atrial stretch a final common pathway to a range of conditions associated with AF such as hypertension,(20) heart failure(12) or valvular heart disease. As a result atrial fibrosis may be diffuse, as measured in the present study by atrial T<sub>1</sub> mapping, or become more prominent in locations such as the posterior wall as demonstrated by DE-MRI. Previous electroanatomic studies have shown a generalized or diffuse reduction in tissue voltage in conditions associated with AF.(20-22) In the present study the interatrial T<sub>1</sub> time at the septum provided a reliable “window” to the LA.(23) Atrial T<sub>1</sub> time shortened with AF burden and with ageing, consistent with prior studies relating fibrotic remodeling to these conditions.(21,24)

#### *Clinical implications*

In the present study, the atrial T<sub>1</sub> time was predictive of AF ablation outcome. In fact, an atrial T<sub>1</sub> time of >260ms was associated with a 96% single procedure success following catheter ablation.

Atrial T<sub>1</sub> time may have greater prognostic value than traditional risk factors for arrhythmia recurrence following catheter ablation, including hypertension, congestive heart failure, and reduced LV EF. These risk factors are associated with structural and electrical LA remodeling but serve as surrogates and not direct measures of underlying arrhythmogenic substrate.(24) In contrast, atrial T<sub>1</sub> time is a quantitative measure of structural remodeling which provides incremental information with potential utility in tailoring ablation strategies to individuals.

#### *Study Limitations*

Atrial T<sub>1</sub> mapping was only possible at the septum given the limits of image resolution. A higher magnetic field (3-T) would allow greater resolution of atrial myocardium and may facilitate both regional and global T<sub>1</sub> mapping. Atrial T<sub>1</sub> time reflects accumulation of gadolinium in the extracellular compartment, but interpatient comparison may be affected by a number of factors, including contrast dose, time post

contrast administration, GFR, haematocrit and heart rate. . Recently Gai and co-workers examined the confounding impact of all these factors in the assessment of myocardial post-contrast  $T_1$  time using a multicompartment model similar to that used in positron emission tomography.(25) They demonstrated the majority of variation in  $T_1$  time was due to contrast dose, followed by scan delay time post contrast administration and then GFR, whereas the impacts of haematocrit and heart rate were negligible. In our study, contrast dose and time post contrast were kept constant for each patient, and the three groups were well matched with respect to GFR, making it unlikely these factors had any significant impact on our study findings. This is further supported by the observation in our study that none of these potential confounders demonstrated a significant relationship with estimated atrial  $T_1$  time.

### *Conclusion*

Atrial fibrosis is the hallmark of structural remodeling and is associated with AF recurrence following medical intervention. Atrial  $T_1$  time as measured using CMR provides an index of diffuse atrial fibrosis that correlates with tissue voltage, AF type and clinical outcomes following catheter ablation.

## References

1. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. *Circulation* 1995;92:1954-68.
2. Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. *Physiol Rev* 2011;91:265-325.
3. Oakes RS, Badger TJ, Kholmovski EG, et al. Detection and quantification of left atrial structural remodeling with delayed-enhancement magnetic resonance imaging in patients with atrial fibrillation. *Circulation* 2009;119:1758-67.
4. Scholz TD, Fleagle SR, Burns TL, Skorton DJ. Nuclear magnetic resonance relaxometry of the normal heart: relationship between collagen content and relaxation times of the four chambers. *Magn Reson Imaging* 1989;7:643-8.
5. Grover-McKay M, Scholz TD, Burns TL, Skorton DJ. Myocardial collagen concentration and nuclear magnetic resonance relaxation times in the spontaneously hypertensive rat. *Invest Radiol* 1991;26:227-32.
6. Iles L, Pfluger H, Phrommintikul A, et al. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. *J Am Coll Cardiol* 2008;52:1574-80.
7. Saranathan M, Rochitte CE, Foo TK. Fast, three-dimensional free-breathing MR imaging of myocardial infarction: a feasibility study. *Magn Reson Med* 2004;51:1055-60.
8. Lee G, Sparks PB, Morton JB, et al. Low risk of major complications associated with pulmonary vein antral isolation for atrial fibrillation: results of 500 consecutive ablation procedures in patients with low prevalence of structural heart disease from a single center. *J Cardiovasc Electrophysiol* 2011;22:163-8.
9. Medi C, Sparks PB, Morton JB, et al. Pulmonary vein antral isolation for paroxysmal atrial fibrillation: results from long-term follow-up. *J Cardiovasc Electrophysiol* 2011;22:137-41.
10. Takahashi Y, Rotter M, Sanders P, et al. Left atrial linear ablation to modify the substrate of atrial fibrillation using a new nonfluoroscopic imaging system. *Pac Clin Electrophys* 2005;28 Suppl 1:S90-3.

11. Calkins H, Kuck KH, Cappato R, et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society. *Heart Rhythm* 2012;9:632-96 e21.
12. Li D, Fareh S, Leung TK, Nattel S. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. *Circulation* 1999;100:87-95.
13. Lau DH, Mackenzie L, Kelly DJ, et al. Hypertension and atrial fibrillation: evidence of progressive atrial remodeling with electrostructural correlate in a conscious chronically instrumented ovine model. *Heart Rhythm* 2010;7:1282-90.
14. Ausma J, van der Velden HM, Lenders MH, et al. Reverse structural and gap-junctional remodeling after prolonged atrial fibrillation in the goat. *Circulation* 2003;107:2051-8.
15. Verheule S, Sato T, Everett Tt, et al. Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-beta1. *Circ Res* 2004;94:1458-65.
16. Kallergis EM, Manios EG, Kanoupakis EM, et al. Extracellular matrix alterations in patients with paroxysmal and persistent atrial fibrillation: biochemical assessment of collagen type-I turnover. *J Am Coll Cardiol* 2008;52:211-5.
17. Wang GD, Shen LH, Wang L, et al. Relationship between integrated backscatter and atrial fibrosis in patients with and without atrial fibrillation who are undergoing coronary bypass surgery. *Clin Cardiol* 2009;32:E56-61.

18. Daccarett M, Badger TJ, Akoum N, et al. Association of left atrial fibrosis detected by delayed-enhancement magnetic resonance imaging and the risk of stroke in patients with atrial fibrillation. *J Am Coll Cardiol* 2011;57:831-8.
19. Kuppahally SS, Akoum N, Badger TJ, et al. Echocardiographic left atrial reverse remodeling after catheter ablation of atrial fibrillation is predicted by preablation delayed enhancement of left atrium by magnetic resonance imaging. *Am Heart J* 2010;160:877-84.
20. Kistler PM, Sanders P, Dodic M, et al. Atrial electrical and structural abnormalities in an ovine model of chronic blood pressure elevation after prenatal corticosteroid exposure: implications for development of atrial fibrillation. *Eur Heart J* 2006;27:3045-56.
21. Kistler PM, Sanders P, Fynn SP, et al. Electrophysiologic and electroanatomic changes in the human atrium associated with age. *J Am Coll Cardiol* 2004;44:109-16.
22. Sanders P, Morton JB, Davidson NC, et al. Electrical remodeling of the atria in congestive heart failure: electrophysiological and electroanatomic mapping in humans. *Circulation* 2003;108:1461-8.
23. Teh AW, Kalman JM, Lee G, et al. Electroanatomic remodelling of the pulmonary veins associated with age. *Europace* 2012;14:46-51.
24. Kumar S, Teh AW, Medi C, et al. Atrial remodeling in varying clinical substrates within beating human hearts: Relevance to atrial fibrillation. *Prog Biophys Mol Biol* 2012.
25. Gai N, Turkbey EB, Nazarian S, et al. T1 mapping of the gadolinium-enhanced myocardium: adjustment for factors affecting interpatient comparison. *Magnet Reson Med* 2011;65:1407-15.

## Figure Legends

### *Figure 1: Calculation of Myocardial T<sub>1</sub> Time at the Interatrial Septum*

A region of interest (ROI) was drawn around the interatrial septal myocardium in the 10 images obtained from the T<sub>1</sub> mapping sequence performed in the long-axis 4-chamber view (A). Signal intensities for each ROI (1 to 10) were curve-fitted to an exponential recovery curve (B) to obtain the atrial T<sub>1</sub> time (vertical red line), which reflects the specific time decay constant when hydrogen nuclei protons within the ROI recover approximately 63% of their longitudinal magnetization equilibrium value in a static magnetic field.

### *Figure 2: Creation of Left Atrial Voltage Map*

A LA electroanatomic map (A) was created using the Ensite NavX system (St Jude Medical), then integrated with the segmented left atrigram obtained by CMR (B). A second LA map color-coded for tissue voltage was then created during distal CS pacing at 600 ms (C). Points were acquired evenly throughout the LA body. The pulmonary veins and LA appendage were excluded. PA – posterior-anterior, RAO – right anterior oblique, LSPV – left superior pulmonary vein, LIPV – left inferior pulmonary vein, RSPV – right superior pulmonary vein, RIPV – right inferior pulmonary vein, LS – left septal region.

### *Figure 3: Intra- and Inter-observer Correlation and Agreement for Atrial T<sub>1</sub> Time*

Linear regression (A) and Bland-Altman plot (B) for intra-observer atrial T<sub>1</sub> times ( $R^2=0.95$ ,  $p<0.001$ ; mean bias 1, 95% limits -21 to 24). Linear regression (C) and Bland-Altman plot (D) for inter-observer atrial T<sub>1</sub> times ( $R^2=0.93$ ,  $p<0.001$ ; mean bias 1, 95% limits -27 to 28). For all graphs,  $n=30$  (10 controls, 10 PAF subjects, and 10 PeAF subjects).

### *Figure 4: Post-contrast Atrial T<sub>1</sub> Times and Voltage Indices*

Atrial T<sub>1</sub> time correlated positively with mean septal voltage (n=23, R<sup>2</sup>=0.48, p<0.001) (A) and mean LA voltage (n=23, R<sup>2</sup>=0.41, p<0.001) (B). Atrial T<sub>1</sub> time differed between all groups (307±39 vs 260±31 vs 240±31 ms, p<0.001) (C).

*Figure 5: Freedom from Recurrent Atrial Arrhythmia by Atrial T<sub>1</sub> Time*

Kaplan Meier analysis demonstrated freedom from recurrent atrial arrhythmia was greater in patients with atrial T<sub>1</sub> time above versus below 260 ms (96% vs 68%, p<0.05).

## Tables

Table 1: Subject characteristics

	Control (n=20)	Paroxysmal AF (n=71)	Persistent AF (n=41)	p value
General characteristics				
Age, years	54±13	58±10	57±11	0.45
Male gender, n (%)	13 (65)	52 (74)	34 (83)* †	<0.05
Body mass index, kg/m <sup>2</sup>	24±3	28±4*	28±4*	<0.01
Resting heart rate, beats/min	54±26	66±15	69±16	0.10
Estimated GFR, ml/min	91±15	91±13	87±17	0.85
Hematocrit, L/L	0.42±0.03	0.42±0.04	0.41±0.09	0.81
CHA <sub>2</sub> DS <sub>2</sub> -Vasc Score	-	1.1±1.1	1.3±1.1	0.23
Co-morbidities, n (%)				
Congestive heart failure	-	5 (7)	14 (34)†	<0.001
Coronary artery disease	-	8 (11)	6 (15)	0.69
Diabetes	-	1 (1)	1 (2)	0.51
Hypertension	-	23 (32)	14 (31)	0.85
Medications, n (%)				
ACE-inhibitor	-	22 (31)	22 (54)†	<0.05
Aldosterone antagonist	-	0 (0)	3 (7)	<0.05
β-blocker	-	42 (60)	30 (73)	0.16
Antiarrhythmics failed	-	1.5±0.7	1.3±0.6†	0.36
CMR findings				
LA size, cm <sup>2</sup>	22±4	25±6	30±7*†	<0.001
LV EF, %	63±4	60±7	56±10*†	<0.01
LV EDV index, ml/m <sup>2</sup>	83±12	77±23	86±17	0.12
LV mass index, g/m <sup>2</sup>	54±13	53±14	56±19	0.18

\*Significant difference compared to the control group. †Significant difference compared to the paroxysmal group.

*Table 2. Relationship Between Atrial T<sub>1</sub> Time and Subject Characteristics Among Controls*

	Univariate model		
	F	R <sup>2</sup>	p value
Age, years	0.09	0.01	0.76
Male gender	0.00	0.00	0.99
Body mass index, kg/m <sup>2</sup>	0.79	0.05	0.39
Resting heart rate, beats/min	2.11	0.12	0.17
Estimated GFR, ml/min	0.40	0.53	0.53
Hematocrit, L/L	0.03	0.00	0.86

Simple linear regression revealed no significant predictors of atrial T<sub>1</sub> time among subject characteristics for healthy controls (n=20).

Table 3: Predictors of Atrial T<sub>1</sub> Time By Simple and Multiple Linear Regression

	Univariate Model			Multivariate Model			
	F	R <sup>2</sup>	p value	B	SE B	β	p value
Age, years	7.21	0.05	<0.01	-0.67	0.33	-0.16	<0.05
Male gender	0.06	0.00	0.80	-	-	-	-
Body mass index, kg/m <sup>2</sup>	8.61	0.06	<0.01	-1.24	0.84	-0.15	0.14
Resting heart rate, beats/min	1.17	0.01	0.28	-	-	-	-
Estimated GFR, ml/min	0.00	0.00	0.96	-	-	-	-
Hematocrit, L/L	0.63	0.01	0.43	-	-	-	-
CHA <sub>2</sub> DS <sub>2</sub> -Vasc Score	2.43	0.02	0.12	-	-	-	-
Congestive heart failure	0.95	0.01	0.33	-	-	-	-
Coronary artery disease	0.34	0.00	0.56	-	-	-	-
Diabetes	0.59	0.00	0.44	-	-	-	-
Hypertension	0.39	0.00	0.53	-	-	-	-
Any AF	32.14	0.20	<0.001	-42.07	11.15	-0.33	<0.001
Persistent AF	7.02	0.05	<0.01	-2.68	7.85	-0.03	0.73
AF duration, years	6.72	0.06	<0.05	-1.59	0.61	-0.21	<0.05
LA size, cm <sup>2</sup>	2.03	0.02	0.16	-	-	-	-
LV EF, %	5.03	0.04	<0.05	0.66	0.45	0.12	0.15
LV EDV index, ml/m <sup>2</sup>	1.91	0.02	0.15	-	-	-	-
LV mass index, g/m <sup>2</sup>	0.41	0.41	0.52	-	-	-	-

Predictors of atrial T<sub>1</sub> time determined using simple and multiple linear regression (n=132, enter method). Categorical variables were entered into analyses using dummy coding. Univariate predictors with P values of <0.1 were entered into the multivariate model yielding age, a diagnosis of AF, and AF duration as independent predictors (F=9.69, p<0.001).

Table 4: Procedural characteristics

	Paroxysmal AF (n=71)	Persistent AF (n=41)	p value
Procedure duration, min	165±32	186±36	<0.05
Fluoroscopy time, min	26±10	28±9	0.17
Radiation dose, mGy/cm <sup>2</sup>	41922±29938	64987±47139	<0.05
Total ablation time, min	41±12	46±12	0.06
PV isolation, n (%)	71 (100)	41 (100)	1.0
Roof line ablation, n (%)	0 (0)	41 (100)	<0.001
Cavotricuspid isthmus ablation, n (%)	5 (7)	2 (5)	0.90
Intraprocedural DCR, n (%)	14 (21)	25 (64)	< 0.001
Acute reconnection, n (%)	26 (40)	7 (18)	<0.05
Freedom from AF at follow up, n (%)	13 (18)	16 (39)	<0.05
Second ablation procedure, n (%)	6 (9)	7 (17)	0.17

Table 4: Patient characteristics by arrhythmia recurrence at follow-up

	Patients free of arrhythmia recurrence (n=83)	Patients with arrhythmia recurrence (n=29)	p value
Age, years	57±11	59±10	0.34
Male gender, n (%)	66 (80)	20 (71)	0.38
Paroxysmal AF, n (%)	58 (70)	13 (45)	<0.05
AF duration, years	4.6±5.8	6.8±6.5	0.09
Mean heart rate, beats/min	66±15	70±15	0.20
Estimated GFR, ml/min	91±14	87±15	0.21
Body mass index, kg/m <sup>2</sup>	28±4	29±5	0.70
Hypertension, n (%)	24 (29)	13 (45)	0.12
Congestive heart failure, n (%)	11 (13)	8 (28)	0.08
Coronary artery disease, n (%)	10 (12)	4 (14)	0.81
LA size, cm <sup>2</sup>	26±7	28±5	0.09
LV EF, %	59±8	56±8	0.10
LV EDV index, ml/m <sup>2</sup>	82±23	79±16	0.24
LV mass index, ml/m <sup>2</sup>	54±15	56±16	0.89
Atrial T <sub>1</sub> time, ms	245±42	216±32	<0.01
Procedure duration, min	171±33	178±39	0.39
Total ablation time, min	42±12	46±14	0.20
Acute reconnection, n (%)	26 (33)	7 (28)	0.62

Table 5: Univariate and Multivariate Predictors of Freedom from Recurrent Atrial Arrhythmia

	Univariate			Multivariate		
	F	R <sup>2</sup>	p value	B	SE B	p value
Age, years	0.91	0.01	0.34	-	-	-
Male gender	0.78	0.01	0.38	-	-	-
AF category (persistent)	6.02	0.05	<0.05	-1.12	0.54	<0.05
AF duration, years	2.93	0.03	<0.10	-0.08	0.05	0.13
Body mass index, kg/m <sup>2</sup>	3.45	0.03	<0.10	-0.08	0.06	0.19
Coronary artery disease	0.06	0.00	0.81	-	-	-
Congestive heart failure	3.17	0.03	<0.10	0.64	0.73	0.38
Hypertension	2.47	0.02	0.12	-	-	-
Diabetes mellitus	0.70	0.01	0.40	-	-	-
LA size, cm <sup>2</sup>	2.00	0.02	0.16	-	-	-
LV EF, %	2.79	0.02	<0.01	-0.01	0.04	0.80
LV EDV index, ml/m <sup>2</sup>	0.33	0.00	0.57	-	-	-
LV mass index, g/m <sup>2</sup>	0.19	0.00	0.66	-	-	-
Atrial T <sub>1</sub> time, ms	11.50	0.09	<0.01	0.02	0.01	<0.05
Procedure duration, min	0.75	0.01	0.39	-	-	-
Total ablation time, min	1.69	0.02	0.19	-	-	-
Acute Reconnection	1.24	0.00	0.62	-	-	-

Predictors of freedom from recurrent arrhythmia following AF ablation were determined using binary logistic regression (n=112). Univariate predictors with p values of <0.1 were entered into the multivariate model which yielded AF category and atrial T<sub>1</sub> time as independent predictors (adjusted R<sup>2</sup>=0.29, p<0.01).